Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-negative Breast Cancer|HER2-positive Breast Cancer|Recurrent Breast Cancer|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: paclitaxel albumin-stabilized nanoparticle formulation|DRUG: bevacizumab|DRUG: trastuzumab|PROCEDURE: magnetic resonance imaging|PROCEDURE: therapeutic conventional surgery
Sponsor: University of California, Irvine
Collaborators: National Institutes of Health (NIH)|National Cancer Institute (NCI)